Antitumoral-Lipid-Based nanoparticles: A platform for future application in osteosarcoma therapy

Current Pharmaceutical Design

Volumn 21, Issue 42, 2015, Pages 6104-6124

  González Fernández, Yolanda ^a,b   Imbuluzqueta, Edurne ^a,b   Patiño García, Ana ^a,b,c   Blanco Prieto, María J ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b IdiSNA Navarra Institute for Health Research   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Chemotherapy; Doxorubicin; Drug delivery; Lipid nanoparticles; Methotrexate; Osteosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CIXUTUMUMAB; CURCUMIN; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; DOXYCYCLINE; EDELFOSINE; ETOPOSIDE; EVEROLIMUS; FOLINIC ACID; IFOSFAMIDE; LIPID NANOCARRIER; LIPOSOME; METHOTREXATE; MIFAMURTIDE; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; PERIFOSINE; RAPAMYCIN; RIDAFOROLIMUS; ROBATUMUMAB; SOLID LIPID NANOPARTICLE; SORAFENIB; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; DRUG CARRIER; LIPID; NANOPARTICLE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER SURGERY; CLINICAL FEATURE; HUMAN; LIPOSOMAL DELIVERY; METASTASIS POTENTIAL; NANOPHARMACEUTICS; ORTHOPEDIC SURGERY; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; BONE NEOPLASMS; CHEMISTRY; CHILD; DRUG DELIVERY SYSTEM; MULTIMODALITY CANCER THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHILD; COMBINED MODALITY THERAPY; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; NANOPARTICLES; OSTEOSARCOMA;

EID: 84957552037     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666151027152534     Document Type: Article

References (255)

1. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014; 64: 83-103.
2. Balis FM. The challenge of developing new therapies for childhood cancers. Oncologist 1997; 2: I-II.
3. Rodríguez-Galindo C. Osteosarcoma. In: Sierrasesúmaga L, Antillón- Klussmann F, Eds. Tratado de Oncología Pediátrica. Madrid: Pearson Educación S.A 2006: pp. 637-51.
4. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 2004 Incidence and Mortality. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute 2007. Available from: (http://www.cdc.gov/cancer/npcr/npcrpdfs/us_cancer_statistics_2004_incidence:and_mortality.pdf).
5. Aljubran AH, Griffin A, Pintilie M, Blackstein M. Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases. Ann Oncol 2009; 20: 1136-41.
6. He H, Ni J, Huang J. Molecular mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett 2014; 7: 1352-62.
7. Estella-Hermoso de Mendoza A, Campanero MA, Mollinedo F, Blanco-Prieto MJ. Lipid nanomedicines for anticancer drug therapy. J Biomed Nanotechnol 2009; 5: 323-43.
8. Date AA, Joshi MD, Patravale VB. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev 2007; 59: 505-21.
9. Klein MJ, Siegal GP. Osteosarcoma: anatomic and histologic variants. Am J Clin Pathol 2006; 125: 555-81.
10. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004; 9: 422-41.
11. Jaffe N. Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res 2009; 152: 239-62.
12. Zhu L, McManus MM, Hughes DP. Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression. Front Oncol 2013; 3: 230.
13. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-27.
14. Tran J, Rak J, Sheehan C, et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 1999; 264: 781-8.
15. Nor JE, Christensen J, Liu J, et al. Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 2001; 61: 2183-8.
16. Lockhart AC, Braun RD, Yu D, et al. Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin Cancer Res 9: 00-00, 2003. Clin Cancer Res 2003; 9: 551-4.
17. DeRenzo C, Gottschalk S. Genetically modified T-cell therapy for osteosarcoma. Adv Exp Med Biol 2014; 804: 323-40.
18. Tarek N, Lee DA. Natural killer cells for osteosarcoma. Adv Exp Med Biol 2014; 804: 341-53.
19. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003; 3: 895-902.
20. Gorlick R, Khanna C. Osteosarcoma. J Bone Miner Res 2010; 25: 683-91.
21. Moore DD, Luu HH. Osteosarcoma. Cancer Treat Res 2014; 162: 65-92.
22. Tan JZ, Schlicht SM, Powell GJ, et al. Multidisciplinary approach to diagnosis and management of osteosarcoma - a review of the St Vincent's Hospital experience. Int Semin Surg Oncol 2006; 3: 38.
23. Yamamoto N, Tsuchiya H. Chemotherapy for osteosarcoma - where does it come from? What is it? Where is it going? Expert Opin Pharmacother 2013; 14: 2183-93.
24. Jaffe N. Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma. Adv Exp Med Biol 2014; 804: 1-30.
25. Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979; 43: 2163-77.
26. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004; 9: 422-41.
27. Yang F, Teves SS, Kemp CJ, Henikoff S. Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta 2014; 1845: 84-9.
28. Merino J, Madero L. Quimioterapia del cáncer pediátrico. In: Madero L. MA, Ed. Hematología y Oncología Pediátricas.: Ergón SA 1997; pp. 275-308.
29. Shi Y, Moon M, Dawood S, McManus B, Liu PP. Mechanisms and management of doxorubicin cardiotoxicity. Herz 2011; 36: 296-305.
30. Xu F, Wang F, Yang T, Sheng Y, Zhong T, Chen Y. Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells. Cancer Cell Int 2014; 14: 538.
31. Hum MC, Kamen BA. Folate, antifolates, and folate analogs in pediatric oncology. Invest New Drugs 1996; 14: 101-11.
32. Sun W, Ma Y, Chen P, Wang D. MicroRNA-10a silencing reverses cisplatin resistance in the A549/cisplatin human lung cancer cell line via the transforming growth factor-beta/Smad2/STAT3/STAT5 pathway. Mol Med Rep 2015; 11(5): 3854-9.
33. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 2014; 740: 364-78.
34. Zhang J, Lu H. Ifosfamide induces acute renal failure via inhibition of the thioredoxin reductase activity. Free Radic Biol Med 2007; 43: 1574-83.
35. Ritter J, Bielack SS. Osteosarcoma. Ann Oncol 2010; 21 (Suppl 7): vii320-5.
36. Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev 2014; 40: 523-32.
37. Merimsky O, Kollender Y, Inbar M, Meller I, Bickels J. Palliative treatment for advanced or metastatic osteosarcoma. ISR Med Assoc J 2004; 6: 34-8.
38. Arias JL, Clares B, Morales ME, Gallardo V, Ruiz MA. Lipidbased drug delivery systems for cancer treatment. Curr Drug Targets 2011; 12: 1151-65.
39. Liu D, Zhang N. Cancer chemotherapy with lipid-based nanocarriers. Crit Rev Ther Drug Carrier Syst 2010; 27: 371-417.
40. Kirby C, Gregoriadis G. Plasma-induced release of solutes from small unilamellar liposomes is associated with pore formation in the bilayers. Biochem J 1981; 199: 251-4.
41. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-77.
42. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS Pharm- SciTech 2011; 12: 62-76.
43. Lasa-Saracibar B, Estella-Hermoso de Mendoza A, Guada M, Dios-Vieitez C, Blanco-Prieto MJ. Lipid nanoparticles for cancer therapy: state of the art and future prospects. Expert Opin Drug Deliv 2012; 9: 1245-61.
44. Müller RH, Lucks JS. inventor. Medication vehicles made of solid lipid particles (solid lipid nanospheres – SLN). European patent EP 0605497 B1 1996 .
45. Gasco MR, inventor. Method for producing solid lipid microspheres having a narrow size distribution. United States patent US5250236 A 1993 .
46. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001; 47: 165-96.
47. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54 (Suppl 1): S131-55.
48. Muller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002; 242: 121-8.
49. Pardeike J, Hommoss A, Muller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009; 366: 170-84.
50. Muchow M, Maincent P, Muller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Develop Ind Pharm 2008; 34: 1394-405.
51. Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs--a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 2004; 113: 151-70.
52. Sharma P, Dube B, Sawant K. Synthesis of cytarabine lipid drug conjugate for treatment of meningeal leukemia: development, characterization and in vitro cell line studies. J Biomed Nanotechnol 2012; 8: 928-37.
53. Olbrich C, Gessner A, Kayser O, Muller RH. Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J Drug Target 2002; 10: 387-96.
54. Neupane YR, Sabir MD, Ahmad N, Ali M, Kohli K. Lipid drug conjugate nanoparticle as a novel lipid nanocarrier for the oral delivery of decitabine: ex vivo gut permeation studies. Nanotechnology 2013; 24: 415102.
55. Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anticancer drug delivery. J Control Release 2010; 148: 135-46.
56. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011; 63: 136-51.
57. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release 2012; 164: 138-44.
58. Beduneau A, Saulnier P, Hindre F, Clavreul A, Leroux JC, Benoit JP. Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab' fragments. Biomaterials 2007; 28: 4978-90.
59. Jain SK, Chaurasiya A, Gupta Y, et al. Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targeting. J Microencapsul 2008; 25: 289-97.
60. Patlolla RR, Vobalaboina V. Folate-targeted etoposideencapsulated lipid nanospheres. J Drug Target 2008; 16: 269-75.
61. Jain A, Agarwal A, Majumder S, et al. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release 2010; 148: 359-67.
62. Yuan H, Miao J, Du YZ, You J, Hu FQ, Zeng S. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm 2008; 348: 137-45.
63. Serpe L, Guido M, Canaparo R, et al. Intracellular accumulation and cytotoxicity of doxorubicin with different pharmaceutical formulations in human cancer cell lines. J Nanosci Nanotechnol 2006; 6: 3062-9.
64. Thorn CF, Oshiro C, Marsh S, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 2011; 21: 440-6.
65. Rivankar S. An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther 2014; 10: 853-8.
66. Wong HL, Bendayan R, Rauth AM, Wu XY. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J Pharm Sci 2004; 93: 1993-2008.
67. Serpe L, Catalano MG, Cavalli R, et al. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm 2004; 58: 673-80.
68. Serpe L, Guido M, Canaparo R, et al. Intracellular accumulation and cytotoxicity of doxorubicin with different pharmaceutical formulations in human cancer cell lines. J Nanosci Nanotechnol 2006; 6: 3062-9.
69. Kuo YC, Liang CT. Catanionic solid lipid nanoparticles carrying doxorubicin for inhibiting the growth of U87MG cells. Colloids Surf B Biointerfaces 2011; 85: 131-7.
70. Kang KW, Chun MK, Kim O, et al. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomedicine 2010; 6: 210-3.
71. Miao J, Du YZ, Yuan H, Zhang XG, Hu FQ. Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells. Colloids Surf B Biointerfaces 2013; 110: 74-80.
72. Ma P, Dong X, Swadley CL, et al. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. J Biomed Nanotechnol 2009; 5: 151-61.
73. Dong X, Mattingly CA, Tseng MT, et al. Doxorubicin and paclitaxel- loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res 2009; 69: 3918-26.
74. Siddiqui A, Gupta V, Liu YY, Nazzal S. Doxorubicin and MBOasGCS oligonucleotide loaded lipid nanoparticles overcome multidrug resistance in adriamycin resistant ovarian cancer cells (NCI/ADR-RES). Int J Pharm 2012; 431: 222-9.
75. Gouaze-Andersson V, Yu JY, Kreitenberg AJ, Bielawska A, Giuliano AE, Cabot MC. Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells. Biochim Biophys Acta 2007; 1771: 1407-17.
76. Freeman MR, Di Vizio D, Solomon KR. The Rafts of the Medusa: cholesterol targeting in cancer therapy. Oncogene 2010; 29: 3745-7.
77. Jain A, Agarwal A, Majumder S, et al. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release 2010; 148: 359-67.
78. Zhou X, Jing J, Peng J, et al. Expression and clinical significance of galectin-3 in osteosarcoma. Gene 2014; 546: 403-7.
79. Mussi SV, Sawant R, Perche F, et al. Novel nanostructured lipid carrier co-loaded with doxorubicin and docosahexaenoic acid demonstrates enhanced in vitro activity and overcomes drug resistance in MCF-7/Adr cells. Pharm Res 2014; 31: 1882-92.
80. Zhang XG, Miao J, Dai YQ, Du YZ, Yuan H, Hu FQ. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int J Pharm 2008; 361: 239-44.
81. Vergote IB, Marth C, Coleman RL. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev 2015; 34(1): 41-52.
82. Yu Y, Chen Z, Dong J, et al. Folate receptor-positive circulating tumor cells as a novel diagnostic biomarker in non-small cell lung cancer. Transl Oncol 2013; 6: 697-702.
83. Yang R, Kolb EA, Qin J, et al. The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate. Clin Cancer Res 2007; 13: 2557-67.
84. Taratula O, Kuzmov A, Shah M, Garbuzenko OB, Minko T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control Release 2013; 171: 349-57.
85. Bertino JR, Goker E, Gorlick R, Li WW, Banerjee D. Resistance mechanisms to methotrexate in tumors. Oncologist 1996; 1: 223-6.
86. Battaglia L, Serpe L, Muntoni E, Zara G, Trotta M, Gallarate M. Methotrexate-loaded SLNs prepared by coacervation technique: in vitro cytotoxicity and in vivo pharmacokinetics and biodistribution. Nanomedicine (Lond) 2011; 6: 1561-73.
87. Zhuang YG, Xu B, Huang F, Wu JJ, Chen S. Solid lipid nanoparticles of anticancer drugs against MCF-7 cell line and a murine breast cancer model. Pharmazie 2012; 67: 925-9.
88. Ruckmani K, Sivakumar M, Ganeshkumar PA. Methotrexate loaded solid lipid nanoparticles (SLN) for effective treatment of carcinoma. J Nanosci Nanotechnol 2006; 6: 2991-5.
89. Paliwal R, Rai S, Vyas SP. Lipid drug conjugate (LDC) nanoparticles as autolymphotrophs for oral delivery of methotrexate. J Biomed Nanotechnol 2011; 7: 130-1.
90. Tian J, Pang X, Yu K, Liu L, Zhou J. Preparation, characterization and in vivo distribution of solid lipid nanoparticles loaded with cisplatin. Pharmazie 2008; 63: 593-7.
91. Doijad RC, Manvi FV, Godhwani DM, Joseph R, Deshmukh NV. Formulation and targeting efficiency of Cisplatin engineered solid lipid nanoparticles. Indian J Pharm Sci 2008; 70: 203-7.
92. Kaijser GP, Beijnen JH, Bult A, Hogeboom MH, Underberg WJ. A systematic study on the chemical stability of ifosfamide. J Pharm Biomed Anal 1991; 9: 1061-7.
93. Dechant KL, Brogden RN, Pilkington T, Faulds D. Ifosfamide/ mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 1991; 42: 428-67.
94. Zhan J, Tian Q, Zhou S. Clinical pharmacology of cyclophosphamide and ifosfamide. Curr Drug Ther 2006; 1: 55-84.
95. Montecucco A, Biamonti G. Cellular response to etoposide treatment. Cancer Lett 2007; 252: 9-18.
96. Joel SP, Clark PI, Heap L, et al. Pharmacological attempts to improve the bioavailability of oral etoposide. Cancer Chemother Pharmacol 1995; 37: 125-33.
97. Lorico A, Rappa G, Finch RA, Yang D, Flavell RA, Sartorelli AC. Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Res 1997; 57: 5238-42.
98. Pandit AA, Dash AK. Surface-modified solid lipid nanoparticulate formulation for ifosfamide: development and characterization. Nanomedicine (Lond) 2011; 6: 1397-412.
99. Zhang T, Chen J, Zhang Y, Shen Q, Pan W. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur J Pharm Sci 2011; 43: 174-9.
100. Wang J, Zhu R, Sun X, Zhu Y, Liu H, Wang SL. Intracellular uptake of etoposide-loaded solid lipid nanoparticles induces an enhancing inhibitory effect on gastric cancer through mitochondriamediated apoptosis pathway. Int J Nanomed 2014; 9: 3987-98.
101. Athawale RB, Jain DS, Singh KK, Gude RP. Etoposide loaded solid lipid nanoparticles for curtailing B16F10 melanoma colonization in lung. Biomed Pharmacother 2014; 68: 231-40.
102. Mohammadi Ghalaei P, Varshosaz J, Sadeghi Aliabadi H. Evaluating cytotoxicity of hyaluronate targeted solid lipid nanoparticles of etoposide on SK-OV-3 Cells. J Drug Deliv 2014; 2014: 746325.
103. Gvozdenovic A, Arlt MJ, Campanile C, et al. CD44 enhances tumor formation and lung metastasis in experimental osteosarcoma and is an additional predictor for poor patient outcome. J Bone Miner Res 2013; 28: 838-47.
104. Khajavinia A, Varshosaz J, Dehkordi AJ. Targeting etoposide to acute myelogenous leukaemia cells using nanostructured lipid carriers coated with transferrin. Nanotechnology 2012; 23: 405101.
105. Nakase M, Inui M, Okumura K, Kamei T, Nakamura S, Tagawa T. P53 gene therapy of human osteosarcoma using a transferrinmodified cationic liposome. Mol Cancer Ther 2005; 4: 625-31.
106. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006; 6: 1075-85.
107. Hattinger CM, Pasello M, Ferrari S, Picci P, Serra M. Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs 2010; 15: 615-34.
108. Beauchamp EM, Platanias LC. The evolution of the TOR pathway and its role in cancer. Oncogene 2013; 32: 3923-32.
109. Zhou Q, Deng Z, Zhu Y, Long H, Zhang S, Zhao J. mTOR/p70S6K signal transduction pathway contributes to osteosarcoma progression and patients' prognosis. Med Oncol 2010; 27: 1239-45.
110. Wang X, Lai P, Zhang Z, et al. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis. Oncol Rep 2014; 32: 382-8.
111. Xie ZG, Xie Y, Dong QR. Inhibition of the mammalian target of rapamycin leads to autophagy activation and cell death of MG63 osteosarcoma cells. Oncol Lett 2013; 6: 1465-9.
112. Mu X, Isaac C, Schott T, Huard J, Weiss K. Rapamycin inhibits ALDH activity, resistance to oxidative stress, and metastatic potential in murine osteosarcoma cells. Sarcoma 2013; 2013: 480713.
113. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50: 799-805.
114. Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005; 65: 2406-11.
115. Bagatell R, Norris R, Ingle AM, et al. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study. Pediatr Blood Cancer 2014; 61: 833-9.
116. Chawla SP, Staddon AP, Baker LH, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 2012; 30: 78-84.
117. Demetri GD, Chawla SP, Ray-Coquard I, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol 2013; 31: 2485-92.
118. Yoo C, Lee J, Rha SY, et al. Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. Invest New Drugs 2013; 31: 1602-8.
119. Fouladi M, Laningham F, Wu J, et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 2007; 25: 4806-12.
120. Fleuren ED, Versleijen-Jonkers YM, Roeffen MH, et al. Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models. Int J Cancer 2014; 135: 2770-82.
121. Schuetze SM, Zhao L, Chugh R, et al. Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma. Eur J Cancer 2012; 48: 1347-53.
122. Fu L, Kim YA, Wang X, et al. Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res 2009; 69: 8967-76.
123. Yao C, Wei JJ, Wang ZY, et al. Perifosine induces cell apoptosis in human osteosarcoma cells: new implication for osteosarcoma therapy? Cell Biochem Biophys 2013; 65: 217-27.
124. Cirstea D, Hideshima T, Rodig S, et al. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin- bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 2010; 9: 963-75.
125. NCT00776867. Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors. Available at: https://clinicaltrials.gov/ct2/show/NCT00776867.
126. NCT01049841. Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors. Available at: https://clinicaltrials.gov/ct2/show/NCT01049841.
127. Kuijjer ML, Peterse EF, van den Akker BE, et al. IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. BMC Cancer 2013; 13: 245,2407-13-245.
128. Burrow S, Andrulis IL, Pollak M, Bell RS. Expression of insulinlike growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 1998; 69: 21-7.
129. Wang YH, Han XD, Qiu Y, et al. Increased expression of insulinlike growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma. J Surg Oncol 2012; 105: 235-43.
130. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50: 1190-7.
131. Wang Y, Lipari P, Wang X, et al. A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol Cancer Ther 2010; 9: 410-8.
132. Weigel B, Malempati S, Reid JM, et al. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer 2014; 61: 452-6.
133. Juergens H, Daw NC, Geoerger B, et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 2011; 29: 4534-40.
134. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009; 69: 7662-71.
135. Quek R, Wang Q, Morgan JA, et al. Combination mTOR and IGF- 1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 2011; 17: 871-9.
136. Schwartz GK, Tap WD, Qin LX, et al. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol 2013; 14: 371-82.
137. Molife LR, Fong PC, Paccagnella L, et al. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer 2010; 103: 332-9.
138. Luk F, Yu Y, Walsh WR, Yang JL. IGF1R-targeted therapy and its enhancement of doxorubicin chemosensitivity in human osteosarcoma cell lines. Cancer Invest 2011; 29: 521-32.
139. Duan Z, Choy E, Harmon D, et al. Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol Cancer Ther 2009; 8: 2122-30.
140. Azuma K, Tanaka M, Uekita T, et al. Tyrosine phosphorylation of paxillin affects the metastatic potential of human osteosarcoma. Oncogene 2005; 24: 4754-64.
141. Shor AC, Keschman EA, Lee FY, et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 2007; 67: 2800-8.
142. Hingorani P, Zhang W, Gorlick R, Kolb EA. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo. Clin Cancer Res 2009; 15: 3416-22.
143. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50: 1198-206.
144. NCT00788125. Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors. Available at: https://clinicaltrials.gov/ct2/show/NCT00788125.
145. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999; 17: 2781-8.
146. Morris CD, Gorlick R, Huvos G, Heller G, Meyers PA, Healey JH. Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clin Orthop Relat Res 2001; (382): 59-65.
147. Maitra A, Wanzer D, Weinberg AG, Ashfaq R. Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer 2001; 92: 677-83.
148. Kilpatrick SE, Geisinger KR, King TS, et al. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol 2001; 14: 1277-83.
149. Anninga JK, van de Vijver MJ, Cleton-Jansen AM, et al. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 2004; 40: 963-70.
150. Ebb D, Meyers P, Grier H, et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. J Clin Oncol 2012; 30: 2545-51.
151. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411: 375-9.
152. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
153. DuBois S, Demetri G. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer 2007; 109: 813-9.
154. Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000; 6: 572-7.
155. Oda Y, Yamamoto H, Tamiya S, et al. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol 2006; 19: 738-45.
156. Charity RM, Foukas AF, Deshmukh NS, Grimer RJ. Vascular endothelial growth factor expression in osteosarcoma. Clin Orthop Relat Res 2006; 448: 193-8.
157. NCT00667342. A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma. Available at: https://clinicaltrials.gov/ct2/show/NCT00667342.
158. Pignochino Y, Grignani G, Cavalloni G, et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 2009; 8: 118,4598-8-118.
159. Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 2012; 23: 508-16.
160. Pignochino Y, Dell'Aglio C, Basirico M, et al. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin Cancer Res 2013; 19: 2117-31.
161. NCT01804374. Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma (SERIO). Available at: https://clinicaltrials.gov/ct2/show/NCT01804374.
162. NCT01946529. Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors. Available at: https://clinicaltrials.gov/ct2/show/NCT01946529.
163. NCT01518413. Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors. Available at: https://clinicaltrials.gov/ct2/show/NCT01518413.
164. Endo-Munoz L, Evdokiou A, Saunders NA. The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis. Biochim Biophys Acta 2012; 1826: 434-42.
165. Diel IJ, Solomayer EF, Bastert G. Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies. Cancer 2000; 88: 3080-8.
166. Ohba T, Cole HA, Cates JM, et al. Bisphosphonates inhibit osteosarcoma- mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL. J Bone Miner Res 2014; 29: 1431-45.
167. Cheng YY, Huang L, Lee KM, Li K, Kumta SM. Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer 2004; 42: 410-5.
168. Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 2005; 104: 2522-9.
169. Goldsby RE, Fan TM, Villaluna D, et al. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Eur J Cancer 2013; 49: 2384-91.
170. Meyers PA, Healey JH, Chou AJ, et al. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer 2011; 117: 1736-44.
171. NCT00691236. Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma (ZOL). Available at: https://clinicaltrials.gov/ct2/show/NCT00691236.
172. NCT00470223. Combination Chemotherapy With or Without Zoledronic Acid in Treating Patients With Osteosarcoma. Available at: https://clinicaltrials.gov/ct2/show/NCT00470223.
173. Koto K, Murata H, Kimura S, et al. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents. Oncol Rep 2010; 24: 233-9.
174. Moriceau G, Ory B, Mitrofan L, et al. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res 2010; 70: 10329-39.
175. Ory B, Moriceau G, Redini F, Heymann D. mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours. Curr Med Chem 2007; 14: 1381-7.
176. Meyers PA, Chou AJ. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma. Adv Exp Med Biol 2014; 804: 307-21.
177. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol 2008; 26: 633-8.
178. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23: 2004-11.
179. Chou AJ, Kleinerman ES, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer 2009; 115: 5339-48.
180. Takimoto CH. New antifolates: pharmacology and clinical applications. Oncologist 1996; 1: 68-81.
181. Purcell WT, Ettinger DS. Novel antifolate drugs. Curr Oncol Rep 2003; 5: 114-25.
182. NCT00119301. Methotrexate, Trimetrexate Glucuronate, and Leucovorin in Treating Patients With Refractory or Recurrent Osteosarcoma. Available at: https://clinicaltrials.gov/ct2/show/NCT00119301.
183. NCT00003776. Combination Chemotherapy and Surgery in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma. Available at: https://clinicaltrials.gov/ct2/show/NCT00003776.
184. O'Day K, Gorlick R. Novel therapeutic agents for osteosarcoma. Expert Rev Anticancer Ther 2009; 9: 511-23.
185. Rollins KD, Lindley C. Pemetrexed: a multitargeted antifolate. Clin Ther 2005; 27: 1343-82.
186. Bodmer N, Walters DK, Fuchs B. Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines. Pediatr Blood Cancer 2008; 50: 905-8.
187. Warwick AB, Malempati S, Krailo M, et al. Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 2013; 60: 237-41.
188. Duffaud F, Egerer G, Ferrari S, Rassam H, Boecker U, Bui-Nguyen B. A phase II trial of second-line pemetrexed in adults with advanced/ metastatic osteosarcoma. Eur J Cancer 2012; 48: 564-70.
189. Yu WX, Tang LN, Lin F, Yao Y, Shen Z. Comparison of pemetrexed plus cisplatin with gemcitabine plus docetaxel in refractory/ metastatic osteosarcoma: Clinical outcomes from a retrospective database monitored in a single institute. Oncol Lett 2014; 8: 2243-8.
190. Rajkumar T, Yamuna M. Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line. Anticancer Drugs 2008; 19: 257-65.
191. Hattinger CM, Stoico G, Michelacci F, et al. Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines. Genes Chromosomes Cancer 2009; 48: 289-309.
192. Lu WD, Qin Y, Yang C, Li L, Fu ZX. Effect of curcumin on human colon cancer multidrug resistance in vitro and in vivo. Clinics (Sao Paulo) 2013; 68: 694-701.
193. Xu D, Tian W, Shen H. P-gp upregulation may be blocked by natural curcuminoids, a novel class of chemoresistance-preventing agent. Mol Med Rep 2013; 7: 115-21.
194. Si M, Zhao J, Li X, Tian JG, Li YG, Li JM. Reversion effects of curcumin on multidrug resistance of MNNG/HOS human osteosarcoma cells in vitro and in vivo through regulation of Pglycoprotein. Chin Med J (Engl) 2013; 126: 4116-23.
195. Lee DS, Lee MK, Kim JH. Curcumin induces cell cycle arrest and apoptosis in human osteosarcoma (HOS) cells. Anticancer Res 2009; 29: 5039-44.
196. Li Y, Zhang J, Ma D, et al. Curcumin inhibits proliferation and invasion of osteosarcoma cells through inactivation of Notch-1 signaling. FEBS J 2012; 279: 2247-59.
197. Walters DK, Muff R, Langsam B, Born W, Fuchs B. Cytotoxic effects of curcumin on osteosarcoma cell lines. Invest New Drugs 2008; 26: 289-97.
198. Chang R, Sun L, Webster TJ. Short communication: selective cytotoxicity of curcumin on osteosarcoma cells compared to healthy osteoblasts. Int J Nanomed 2014; 9: 461-5.
199. NCT00689195. Pilot Study of Curcumin Formulation and Ashwagandha Extract in Advanced Osteosarcoma (OSCAT). Available at: https://clinicaltrials.gov/ct2/show/NCT00689195.
200. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996; 23: 3-15.
201. Herbst RS, Khuri FR. Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treat Rev 2003; 29: 407-15.
202. Leu KM, Ostruszka LJ, Shewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004; 22: 1706-12.
203. Qi WX, He AN, Tang LN, Shen Z, Lin F, Yao Y. Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients. Jpn J Clin Oncol 2012; 42: 427-31.
204. Navid F, Willert JR, McCarville MB, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 2008; 113: 419-25.
205. Song BS, Seo J, Kim DH, Lim JS, Yoo JY, Lee JA. Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience. Pediatr Blood Cancer 2014; 61: 1376-81.
206. Veltkamp SA, Jansen RS, Callies S, et al. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin Cancer Res 2008; 14: 3477-86.
207. Lansakara PDS, Rodriguez BL, Cui Z. Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles. Int J Pharm 2012; 429: 123-34.
208. Chung WG, Sandoval MA, Sloat BR, Lansakara PDS, Cui Z. Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1. J Control Release 2012; 157: 132-40.
209. Wonganan P, Lansakara PDS, Zhu S, et al. Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression. J Control Release 2013; 169: 17-27.
210. Sloat BR, Sandoval MA, Li D, et al. In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles. Int J Pharm 2011; 409: 278-88.
211. Sandoval MA, Sloat BR, Lansakara PDS, et al. EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity. J Control Release 2012; 157: 287-96.
212. Daman Z, Ostad S, Amini M, Gilani K. Preparation, optimization and in vitro characterization of stearoyl-gemcitabine polymeric micelles: a comparison with its self-assembled nanoparticles. Int J Pharm 2014; 468: 142-51.
213. Couvreur P, Stella B, Reddy LH, et al. Squalenoyl nanomedicines as potential therapeutics. Nano Lett 2006; 6: 2544-8.
214. Reddy LH, Marque PE, Dubernet C, Mouelhi SL, Desmaele D, Couvreur P. Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine. J Pharmacol Exp Ther 2008; 325: 484-90.
215. Reddy LH, Dubernet C, Mouelhi SL, Marque PE, Desmaele D, Couvreur P. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. J Control Release 2007; 124: 20-7.
216. Reddy LH, Ferreira H, Dubernet C, et al. Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemiabearing rats: study of mechanisms. Anticancer Drugs 2008; 19: 999-1006.
217. van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 2001; 19: 125-41.
218. Zhang L, Zhang N. How nanotechnology can enhance docetaxel therapy. Int J Nanomed 2013; 8: 2927-41.
219. Gao Y, Yang R, Zhang Z, Chen L, Sun Z, Li Y. Solid lipid nanoparticles reduce systemic toxicity of docetaxel: performance and mechanism in animal. Nanotoxicology 2011; 5: 636-49.
220. Zhang P, Chen L, Zhang Z, Lin L, Li Y. Pharmacokinetics in rats and efficacy in murine ovarian cancer model for solid lipid nanoparticles loading docetaxel. J Nanosci Nanotechnol 2010; 10: 7541-4.
221. Mosallaei N, Jaafari MR, Hanafi-Bojd MY, Golmohammadzadeh S, Malaekeh-Nikouei B. Docetaxel-loaded solid lipid nanoparticles: preparation, characterization, in vitro, and in vivo evaluations. J Pharm Sci 2013; 102: 1994-2004.
222. Yuan Q, Han J, Cong W, et al. Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicity. Int J Nanomed 2014; 9: 4829-46.
223. Liu D, Liu Z, Wang L, Zhang C, Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces 2011; 85: 262-9.
224. Cho HJ, Park JW, Yoon IS, Kim DD. Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake. Int J Nanomed 2014; 9: 495-504.
225. Hu K, Cao S, Hu F, Feng J. Enhanced oral bioavailability of docetaxel by lecithin nanoparticles: preparation, in vitro, and in vivo evaluation. Int J Nanomed 2012; 7: 3537-45.
226. Sanchez-Moreno P, Ortega-Vinuesa JL, Boulaiz H, Marchal JA, Peula-Garcia JM. Synthesis and characterization of lipid immunonanocapsules for directed drug delivery: selective antitumor activity against HER2 positive breast-cancer cells. Biomacromolecules 2013; 14: 4248-59.
227. Liu D, Liu F, Liu Z, Wang L, Zhang N. Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody. Mol Pharm 2011; 8: 2291-301.
228. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4: 807-18.
229. Sun J, Bi C, Chan HM, Sun S, Zhang Q, Zheng Y. Curcuminloaded solid lipid nanoparticles have prolonged in vitro antitumour activity, cellular uptake and improved in vivo bioavailability. Colloids Surf B Biointerfaces 2013; 111: 367-75.
230. Vandita K, Shashi B, Santosh KG, Pal KI. Enhanced apoptotic effect of curcumin loaded solid lipid nanoparticles. Mol Pharm 2012; 9: 3411-21.
231. Kakkar V, Singh S, Singla D, Kaur IP. Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol Nutr Food Res 2011; 55: 495-503.
232. Wang P, Zhang L, Peng H, Li Y, Xiong J, Xu Z. The formulation and delivery of curcumin with solid lipid nanoparticles for the treatment of on non-small cell lung cancer both in vitro and in vivo. Mater Sci Eng C Mater Biol Appl 2013; 33: 4802-8.
233. Zhao X, Chen Q, Liu W, et al. Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer. Int J Nanomed 2014; 10: 257-70.
234. Zhao X, Chen Q, Li Y, Tang H, Liu W, Yang X. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice. Eur J Pharm Biopharm 2015; 93: 27-36.
235. Gonen N, Assaraf YG. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat 2012; 15: 183-210.
236. Berdel WE, Fink U, Rastetter J. Clinical phase I pilot study of the alkyl lysophospholipid derivative ET-18-OCH3. Lipids 1987; 22: 967-9.
237. Gajate C, Mollinedo F. Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET- 18-OCH(3) (edelfosine), a proapoptotic agent in tumor cells. Curr Drug Metab 2002; 3: 491-525.
238. Estella-Hermoso de Mendoza A, Campanero MA, Lana H, et al. Complete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticles. Nanomedicine (Lond) 2012; 7: 679-90.
239. Lasa-Saracibar B, Aznar MA, Lana H, Aizpun I, Gil AG, Blanco- Prieto MJ. Lipid nanoparticles protect from edelfosine toxicity in vivo. Int J Pharm 2014; 474: 1-5.
240. Aznar MA, Lasa-Saracibar B, Estella-Hermoso de Mendoza A, Blanco-Prieto MJ. Efficacy of edelfosine lipid nanoparticles in breast cancer cells. Int J Pharm 2013; 454: 720-6.
241. Estella-Hermoso de Mendoza A, Preat V, Mollinedo F, Blanco- Prieto MJ. In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J Control Release 2011; 156: 421-6.
242. Lasa-Saracibar B, Estella-Hermoso de Mendoza A, Mollinedo F, Odero MD, Blanco-Prieto MJ. Edelfosine lipid nanosystems overcome drug resistance in leukemic cell lines. Cancer Lett 2013; 334: 302-10.
243. González-Fernández Y, Zalacain M, Imbuluzqueta E, Sierrasesúmaga L, Patiño-García A, Blanco-Prieto MJ. Lipid nanoparticles enhance the efficacy of chemotherapy in primary and metastatic human osteosarcoma cells. JDDST 2015; doi:10.1016/j.jddst.2015.08.004.
244. Steinmann P, Walters DK, Arlt MJ, et al. Antimetastatic activity of honokiol in osteosarcoma. Cancer 2012; 118: 2117-27.
245. Shigemura K, Arbiser JL, Sun SY, et al. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer 2007; 109: 1279-89.
246. Park EJ, Min HY, Chung HJ, et al. Down-regulation of c- Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells. Cancer Lett 2009; 277: 133-40.
247. Leeman-Neill RJ, Cai Q, Joyce SC, et al. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clin Cancer Res 2010; 16: 2571-9.
248. Wen J, Fu AF, Chen LJ, et al. Liposomal honokiol inhibits VEGFD- induced lymphangiogenesis and metastasis in xenograft tumor model. Int J Cancer 2009; 124: 2709-18.
249. Crane C, Panner A, Pieper RO, Arbiser J, Parsa AT. Honokiolmediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function. J Immunother 2009; 32: 585-92.
250. Xu D, Lu Q, Hu X. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol. Cancer Lett 2006; 243: 274-80.
251. Ishitsuka K, Hideshima T, Hamasaki M, et al. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood 2005; 106: 1794-800.
252. Han HK, Van Anh LT. Modulation of P-glycoprotein expression by honokiol, magnolol and 4-O-methylhonokiol, the bioactive components of Magnolia officinalis. Anticancer Res 2012; 32: 4445-52.
253. Wang XH, Cai LL, Zhang XY, et al. Improved solubility and pharmacokinetics of PEGylated liposomal honokiol and human plasma protein binding ability of honokiol. Int J Pharm 2011; 410: 169-74.
254. Zheng J, Tang Y, Sun M, et al. Characterization, pharmacokinetics, tissue distribution and antitumor activity of honokiol submicron lipid emulsions in tumor-burdened mice. Pharmazie 2013; 68: 41-6.
255. Parhi P, Sahoo SK. Trastuzumab guided nanotheranostics: A lipid based multifunctional nanoformulation for targeted drug delivery and imaging in breast cancer therapy. J Colloid Interface Sci 2015; 451: 198-211.